Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege

Transplantation

Volumn 87, Issue 12, 2009, Pages 1778-1786

  Cheng, Xuyang ^a   Dai, Hehua ^a   Wan, Ni ^a   Moore, Yolonda ^a   Vankayalapati, Ramakrishna ^a   Dai, Zhenhua ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Costimulation; Immune privilege and transplantation; T cells

Indexed keywords

LIGAND; PROGRAMMED DEATH 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; GRAFT SURVIVAL; IMMUNE RESPONSE; KIDNEY CAPSULE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEMINIFEROUS TUBULE; SPERMATID; SPERMATOCYTE; T LYMPHOCYTE; TESTIS;

ANIMALS; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DNA PRIMERS; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TESTIS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 67649592395     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a75633     Document Type: Article

References (61)

1. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 58.
2. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. II. F1 lymphocyte-induced immune deviation. J Immunol 1977; 118: 809.
3. Head JR, Neaves WB, Billingham RE. Reconsideration of the lymphatic drainage of the rat testis. Transplantation 1983; 35: 91.
4. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
5. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
6. Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000; 6: 493.
7. Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001; 2: 917.
8. Allison J, Georgiou HM, Strasser A, et al. Transgenic expression of CD95 ligand on islet beta cells induces granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
9. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
10. Judge TA, Desai NM, Yang Z, et al. Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 1998; 66: 426.
11. Li XY, D'Orazio LT, Niederkorn JY. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunology 1996; 89: 34.
12. Beauregard C, Stevens C, Mayhew E, et al. Cutting edge: Atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol 2005; 174: 6577.
13. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714.
14. Wilbanks GA, Mammolenti MM, Streilein JW. Studies on the induction of anterior chamber associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-b. Eur J Immunol 1992; 22: 165.
15. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813.
16. Ksander BR, Streilein JW. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J Immunol 1990; 145: 2057.
17. + T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 2003; 171: 1266.
18. Sonoda KH, Exley M, Snapper S, et al. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999; 190: 1215.
19. Jukes JP, Wood KJ, Jones ND. Natural killer T cells: A bridge to tolerance or a pathway to rejection? Transplantation 2007; 84: 679.
20. Bobzien B, Yasunami Y, Majercik M, et al. Intratesticular transplants of islet xenografts (rat to mouse). Diabetes 1983; 32: 213.
21. Selawry HP, Whittington K. Extended allograft survival of islets grafted into intra-abdominally placed testis. Diabetes 1984; 33: 405.
22. Cameron DF, Whittington K, Schultz RE, et al. Successful islet/abdominal testis transplantation does not require Leydig cells. Transplantation 1990; 50: 649.
23. Selawry HP, Whittington KB, Bellgrau D. Abdominal intratesticular islet xenograft survival in rats. Diabetes 1989; 38: 220.
24. Nasr IW, Wang Y, Gao G, et al. Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells. J Immunol 2005; 174: 6161.
25. Salvalaggio PR, Deng S, Ariyan CE, et al. Islet filtration: A simple and rapid new purification procedure that avoids ficoll and improves islet mass and function. Transplantation 2002; 74: 877.
26. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63.
27. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005; 174: 3408.
28. + T cells via a CD30- dependent mechanism. J Clin Invest 2004; 113: 310.
29. Liu ZW, Dai H, Wan N, et al. Suppression of memory CD8 T cell generation and function by tryptophan catabolism. J Immunol 2007; 178: 4260.
30. + T cells. J Immunol 2008; 180: 2886.
31. Chalasani G, Dai Z, Konieczny B, et al. Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Nat Acad Sci USA 2002; 99: 6175.
32. Khoury SJ, Sayegh MH. The role of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004; 20: 529.
33. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883.
34. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005; 202: 231.
35. Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PDL1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706.
36. Shen L, Jin Y, Freeman GJ, et al. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol 2007; 179: 3672.
37. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261.
38. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-g-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection epidodes. J Immunol 1999; 163: 2267.
39. + T cells is CD154 blockade resistant: Therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 4667.
40. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413.
41. Wang Y, Dai H, Liu Z, et al. Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade. Am J Transplant 2006; 6: 2851.
42. Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002; 169: 6546.
43. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171: 6929.
44. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 costimulation induces long-term islet allograft survival. Transplantation 2003; 76: 994.
45. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vitro. J Immunol 2005; 174: 6648.
46. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006; 177: 5928.
47. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007; 179: 5204.
48. Wang L, Han R, Hancock WW. Programmed cell death-1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur J Immunol 2007; 37: 2983.
49. Yang J, Popoola J, Khandwala S, et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 2008; 117: 660.
50. + T cells to transplanted tissue. J Immunol 2008; 181: 5313.
51. Subudhi SK, Zhou P, Yerian LM, et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004; 113: 694.
52. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365.
53. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839.
54. Dal Secco V, Riccioli A, Padula F, et al. Mouse Sertoli cells display phenotypical and functional traits of antigen-presenting cells in response to interferon gamma. Biol Reprod 2008; 78: 234.
55. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2003; 10: 87.
56. + T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol 2004; 172: 5456.
57. Zhang Y, Joe G, Hexner E, et al. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol 2005; 174: 3051.
58. Zhang Q, Chen Y, Fairchild RL, et al. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol 2006; 176: 770.
59. + T cell help. J Immunol 2006; 176: 2316.
60. Vu MD, Clarkson MR, Yagita H, et al. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006; 176: 1394.
61. Bingaman AW, Farber DL. Memory T cells in transplantation: Generation, function, and potential role in rejection.AmJ Transplant 2004; 4: 846.